Predictors and characteristics of asthma exacerbations on biologic therapy

- Cook, Alistair James

Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients

- Thomas, Dennis, McDonald, Vanessa M., Gillman, Andrew, Hew, Mark, Hodge, Sandra, James, Alan, Jenkins, Christine, Katelaris, Constance H., Katsoulotos, Gregory P., Langton, David, Lee, Joy, Marks, Guy, Stevens, Sean, Peters, Matthew, Radhakrishna, Naghmeh, Reynolds, Paul N., Rimmer, Janet, Sivakumaran, Pathmanathan, Upham, John W., Wark, Peter, Yang, Ian A., Gibson, Peter G., Harvey, Erin S., Baraket, Melissa, Bardin, Philip, Bowden, Jeffrey J., Bowler, Simon, Chien, Jimmy, Chung, Li Ping

Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma

- Kritikos, Vicky, Harvey, Erin S., Thomas, Dennis, Gibson, Peter G., Australian Mepolizumab Registry Investigators,, Stevens, Sean, Katelaris, Constance H., Langton, David, Rimmer, Janet, Farah, Claude S., Gillman, Andrew, Hew, Mark, Radhakrishna, Naghmeh

Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics

- Malik, Bilal, Bartlett, Nathan W., Upham, John W., Nichol, Kristy S., Harrington, John, Wark, Peter A. B.

Type 2 Innate Lymphoid Cell Dysfunction in Severe Asthma and Response to Treatment with Mepolizumab and Omalizumab

- Malik Awan, Bilal

Imaging for precision medicine: can V-P SPECT measure mepolizumab response in asthma?

- McDonald, Vanessa M., Urroz, Paola D., Bajc, Marika, Rutherford, Natalie, Brooker, Bree, Gibson, Peter G.

Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry

- Thomas, Dennis, Harvey, Erin S., Bardin, Philip, Peters, Matthew, Reynolds, Paul N., Langton, David, Baraket, Melissa, Bowden, Jeffrey J., Bowler, Simon, Chien, Jimmy, Chung, Li Ping, Farah, Claude S., McDonald, Vanessa M., Wark, Peter A. B., Gibson, Peter G., Katsoulotos, GP, Lee, J, Radhakrishna, N, Reddel, HK, Rimmer, J, Sivakumaran, P, Wark, PAB, Gibson, PG, Stevens, Sean, Upham, John W., Katelaris, Constance H., Kritikos, Vicky, Gillman, Andrew, Harrington, John, Hew, Mark

Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions

- Gibson, Peter G., Prazma, Charlene M., Chupp, Geoffrey L., Bradford, Eric S., Forshag, Mark, Mallett, Stephen A., Yancey, Steve W., Smith, Steven G., Bel, Elisabeth H.

Mepolizumab effectiveness and identification of super-responders in severe asthma

- Harvey, Erin S., Langton, David, Katelaris, Constance, Stevens, Sean, Farah, Claude S., Gillman, Andrew, Harrington, John, Hew, Mark, Kritikos, Vicky, Radhakrishna, Naghmeh, Bardin, Philip, Peters, Matthew, Reynolds, Paul N., Upham, John W., Baraket, Melissa, Bowler, Simon, Bowden, Jeffrey, Chien, Jimmy, Chung, Li Ping, Grainge, Christopher, Jenkins, Christine, McDonald, Vanessa M., Wark, Peter A. B., Gibson, Peter G.

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

- Khatri, Sumita, Moore, Wendy, Gibson, Peter G., Leigh, Richard, Bourdin, Arnaud, Maspero, Jorge, Barros, Manuel, Buhl, Roland, Howarth, Peter, Albers, Frank C., Bradford, Eric S., Gilson, Martyn, Price, Robert G., Yancey, Stephen W., Ortega, Hector